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On 20-21st May 2015, more than 150 people with an inter-
est in core outcome sets (COS) gathered at the University
of Calgary in Alberta, Canada for the fifth meeting of the
COMET Initiative. This was the first annual COMET
meeting in North America, and the COMET Management
Group are grateful to Cochrane Canada for facilitating the
meeting and an excellent joint session on the second day.
As well as participants from Canada and the USA, people
came from Australia, Brazil, Germany, Portugal and
the UK.
Over the next two days, the invited plenary talks were
complemented by workshops, posters and contributed
presentations. Theresa Radwell (Alberta Cancer Founda-
tion) opened the meeting, welcoming all to Calgary and
introducing the importance of engaging patients within
research and outcome selection. Paula Williamson
(COMET Management Group) then spoke about the
COMET Initiative, emphasising that COMET is keen to
avoid unnecessary duplication of effort and to facilitate the
development of COS. The participants were then intro-
duced to important methodological issues in COS through
a series of presentations. John Marshall (St. Michael’s
Hospital, Toronto) provided a critical care perspective and
highlighted that mortality is not always the most impor-
tant outcome from a patient perspective. Amy Hoang-Kim
(University of Toronto) presented a recommendation for a
minimal set of core domains for use in distal radius
fracture clinical practice and research. Moving on to
nephrology, Jonathan Craig and Allison Tong (University
of Sydney) overviewed existing standardized outcomes,
with preliminary results showing how dialysis free time
was the most important outcome to haemodialysis
patients.
One of the novel additions in COMET V was a panel
discussion showing the importance of COS to different
stakeholders. John Fletcher (Canadian Medical Association
Journal) described the pros and cons of COS from an edi-
tor’s perspective. Jordi Pardo (OMERACT) outlined the
OMERACT process for developing a COS. Carole Légaré
(Health Canada) identified the problems seen by regula-
tors because of inconsistency of safety reporting. John
Marshall (Canadian Critical Care Trials Group) spoke
about challenging issues faced by the critical care research
community. Mike Clarke (COMET) brought all of this
together by highlighting the resources that are available
through COMET to assist in the development and evalua-
tion of COS. The ensuing discussion highlighted the bene-
fits of COS for journals, how stakeholder involvement and
international harmonisation are essential to COS develop-
ment, the need to consider barriers to uptake of COS for
researchers, and recognition of the need for a COS that is
in no way restrictive.
The afternoon began with David Moher (Ottawa Hospi-
tal Research Institute) speaking about the EQUATOR
network, which aims to maximise the value of research by
improving conduct and reporting. David highlighted how
the evaluation of reporting guidleines and COS is critical.
He was followed by a series of presentations which centred
around outcomes for paediatric trials. Zafira Bhaloo
(University of Alberta) emphasised how the reporting of
primary outcomes in pediatric trials is inadequate and
encouraged higher standards for reporting and informed
selection of outcomes and their measures. Michele Hamm
(University of Alberta) discussed how the use of social
media to identify patient-centred outcomes in child health
did not result in broad reach as a stakeholder engagement
strategy. Mufiza Kapadia (The Hospital for Sick Children)
ended the session by stressing the importance of involving
parents and children in COS development.
Alongside the 17 posters that were available for viewing
throughout the first day, four of the people who had
submitted abstracts had been selected to give a contribu-
ted talk. These began with Carina Benstom (University
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Hospital RWTH Aachen) who highlighted how the pro-
blems caused by inconsistent outcome measures in clinical
trials are hardly recognised. Chris Hylton (PaCER) spoke
about improvements in the results of patient experiences
and outcome analysis, from involving patient and commu-
nity engagement researchers. Sally Crowe (Crowe Associ-
ates Ltd) continued the patient theme, by speaking about
how workshops offer context and depth for talking about
outcomes. The final contributed talk came from Thomas
Kelley (International Consortium for Health Outcomes
Measurement) who explained how ICHOM’s mission is to
define global standard sets of outcome measures that
really matter to patients for the most relevant medical
conditions. Mike Clarke (COMET Management Group)
closed the first day with a presentation about COMET in
Canada, which highlighted what Canada can do to
increase the use of COS in research, for example by help-
ing to persuade funders that COS should be used in
research.
The second day (21st May) was shared with Cochrane
Canada and the opening of their Annual Symposium. The
opening of the joint session was marked by memories of
Dave Sackett and his contribution to evidence based
healthcare. Following a minute’s silence for the many
friends, colleagues and admirers of Dave to remember
him, the scientific session began with Kay Dickersin (John
Hopkins University) highlighting how groundwork needs
to be laid in subject areas where there are a lack of COS
and how new methods need to be explored for developing
COS. Mike presented findings from a survey of outcomes
in Cochrane Reviews, showing the wide variation in out-
comes and the lack of COS, at least up to 2013. Holger
Schünemann (McMaster University) closed the plenary
session by providing an overview of the GRADE evidence
to decision frameworks.
Following a break, the participants headed off for one of
three COMET workshops. Paula Williamson led the first
of these, which focused on the methods for developing
what to measure in COS. The workshop introduced meth-
odological issues and considerations involved in develop-
ing COS. Workshop 2 was led by Mike Clarke and looked
at how COS might be used for randomised trials and
Cochrane Reviews. Bridget Young (University of Liver-
pool) led the third workshop providing an interactive
opportunity for the participants to identify the challenges
that researchers may encounter when planning to involve
patients and carers in COS development.
COMET V allowed a wide variety of stakeholders with
an interest in COS development to meet and share experi-
ences, findings, and plans with others. It brought together
key scientists and consumers responsible for developing
and implementing COS. Patient involvement emerged as a
major focus of the meeting with an emphasis on engaging
the relevant stakeholders early in the process of COS
development. Thoughts were offered for how COMET
can evolve both in Canada and the rest of the world. And,
challenging questions were posed throughout the meeting,
including: How can we ensure that COS are well devel-
oped in the first place? Is there a magic number of out-
comes to be included in a COS and, if so, what is it? As
COMET looks forward to COMET VI, it will seek to meet
these challenges, guided by an International Advisory
Group, which will include Peter Tugwell (University of
Ottawa), one of the founders of OMERACT.
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